Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Angelalign TechnologyFRA:77D -1.96%75 EV-to-EBITDA is 49.96 as of Aug. 15, 2026, which is 49% above its 10-year median of 33.61. GuruFocus rates FRA:77D with a GF Score™ of 75/100 and a GF Value™ of €11.67 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Angelalign Technology ranks worse than 88.74% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Angelalign Technology's enterprise value is €1,437.2 Mil.
Angelalign Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €28.8 Mil. Therefore, Angelalign Technology's EV-to-EBITDA for today is 49.96.
The historical rank and industry rank for Angelalign Technology's EV-to-EBITDA or its related term are showing as below:
FRA:77D'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.51 Med: 33.61 Max: 283.08
Current: 49.79
During the past 8 years, the highest EV-to-EBITDA of Angelalign Technology was 283.08. The lowest was 10.51. And the median was 33.61.
FRA:77D's EV-to-EBITDA is ranked worse than 88.74% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.89
vs FRA:77D: 49.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Angelalign Technology's PE Ratio (TTM) for today is calculated as:
Angelalign Technology's share price for today is €10.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Angelalign Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.146.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Angelalign Technology EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Angelalign Technology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:77D vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Angelalign Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Angelalign Technology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Angelalign Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Angelalign Technology's EV-to-EBITDA falls into.
Angelalign Technology's current Enterprise Value is €1,437.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Angelalign Technology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €28.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angelalign Technology (FRA:77D) has a EV-to-EBITDA of 49.96 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Angelalign Technology. This is 49% above median its historical median of 33.61. Over the past decade, Angelalign Technology's EV-to-EBITDA has ranged from 10.51 to 283.08. According to the industry distribution chart, Angelalign Technology ranks #457 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 88.7%.
Is Angelalign Technology's EV-to-EBITDA too high?
Angelalign Technology's current EV-to-EBITDA of 49.96 is 49% above median its 10-year median of 33.61. Over the past 10 years, this metric has ranged from a low of 10.51 to a high of 283.08. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.89. Angelalign Technology's value of 49.96 is 235.5% above this industry median. Based on the distribution chart, Angelalign Technology ranks #457 out of 515 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Angelalign Technology has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Angelalign Technology ranks #457 out of 515 companies for EV-to-EBITDA. This places Angelalign Technology in the lower half of its industry. The industry median EV-to-EBITDA is 14.89. Angelalign Technology's value of 49.96 is 235.5% above this benchmark. Historically, Angelalign Technology's own EV-to-EBITDA has ranged from 10.51 to 283.08 over the past decade. While the company's 10-year median is 33.61 vs. the industry median of 14.89, Angelalign Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.89, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Angelalign Technology's current EV-to-EBITDA of 49.96 is 235.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Angelalign Technology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Angelalign Technology's current EV-to-EBITDA is 49.96, which is 49% above median its own 10-year median of 33.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.67, compared to a current price of €10.00 — trading 14.3% below its estimated fair value. The current EV-to-EBITDA is 49.96, which is 49% above median its 10-year median of 33.61 and 235.5% above the Medical Devices & Instruments industry median of 14.89. Angelalign Technology's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current EV-to-EBITDA is 49.96 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Angelalign Technology (FRA:77D) Overvalued in 2026?
Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued.
The current stock price of €10.00 is trading 14.3% below its estimated GF Value™ of €11.67.
GuruFocus considers Angelalign Technology to be Modestly Undervalued.
Key valuation signals for FRA:77D:
EV-to-EBITDA: 49.96 (49% above median its 10-year median of 33.61)
GF Value™: €11.67 vs. price of €10.00 (14.3% below fair value)
Industry Position: 235.5% above the Medical Devices & Instruments median (#457 of 515)
No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
75GF Score
Get the complete analysis for FRA:77D
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:77D has been successfully added to your 
